Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
14.4M
-
Number of holders
-
144
-
Total 13F shares, excl. options
-
13.3M
-
Shares change
-
-237K
-
Total reported value, excl. options
-
$543M
-
Value change
-
-$15.1M
-
Put/Call ratio
-
0.04
-
Number of buys
-
60
-
Number of sells
-
-76
-
Price
-
$40.79
Significant Holders of Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) as of Q1 2021
182 filings reported holding ANIK - Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q1 2021.
Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) has 144 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.3M shares
of 14.4M outstanding shares and own 92.28% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.36M shares), KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC (1.22M shares), AMERIPRISE FINANCIAL INC (997K shares), STATE STREET CORP (941K shares), VANGUARD GROUP INC (920K shares), DIMENSIONAL FUND ADVISORS LP (861K shares), RENAISSANCE TECHNOLOGIES LLC (745K shares), MORGAN STANLEY (654K shares), Boston Trust Walden Corp (375K shares), and FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ (256K shares).
This table shows the top 144 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.